How Can Response Patterns to Olumiant Inform Clinical Decision-Making in Severe Alopecia Areata?
Overview
Healthcare professionals typically want to know whether patients with severe alopecia areata will respond to treatment, how long this will take, and how much hair regrowth is possible. Prof. Vañó discusses distinct patterns of response to Olumiant observed in clinical trials and real-world clinical experience, and how these may help guide clinical decision-making and inform patient expectations.
This Class for
- Physician
What I will learn?
What will I learn?
Understand how response patterns to Olumiant may shape treatment decisions and follow-up discussions for patients with severe AA
Disclaimer:
CMAT-39379 | Privacy Policy | PI Information for Olumiant®
This information is intended for Health Care Professionals only.
This content is approved by Eli Lilly and company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission.
If you have any comments on the provided materials please communicate
such to the SFDA on the unified number: 19999
For adverse events and safety reporting:
email: saudi_pharmacovigilance@lilly.com
24 /7 mobile: +966 567 868 843
Working hours Tel: +966 11 461 7800 , Ext: 1
For any product complaints (PCs), suspected counterfeits, or tampering
with Lilly products, please report them via email at
Saudi_productcomplaint@lilly.com 24/7, mobile: +966 567 868 843 working
hours: +966 11 461 7800, Ext: 1
For Lilly product information:
email: SAUDI_MEDINFOQUERIES@lilly.com
For further information, please contact:
Eli Lilly and Company, Scientific Office
P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia.
Tel: +966 11 461 7800
Fax: +966 111 217 9900Lilly and Olumiant® are registered trademarks of Eli Lilly and Company.
© 2026 Eli Lilly and Company. All Rights Reserved.
CMAT-27115
Related Classes
- Atopic Dermatitis in Elderly Patients: Discussing the Safety of Lebrikizumab in an 86-Year-Old Patient.
- Key IL-13 Skin and Itch Data in Moderate-to-Severe AD.
- Atopic Dermatitis in Visible Areas Is a Real Challenge!
- Depth of Response & Stability of Response of Lebrikizumab
- Can You Reach EASI Targets Faster? – AD Case with Prof. Naiem Issa
- Deep Response to IL‑13 and IL‑4/13 Inhibition in AD
- Role of IL‑13 in Atopic Dermatitis (AD)
- Is FACE/Neck AD Treatable? A Real Patient Case with Dr. Fares Alkhayal